These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30849661)

  • 1. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
    Gerds AT; Tauchi T; Ritchie E; Deininger M; Jamieson C; Mesa R; Heaney M; Komatsu N; Minami H; Su Y; Shaik N; Zhang X; DiRienzo C; Zeremski M; Chan G; Talpaz M
    Leuk Res; 2019 Apr; 79():38-44. PubMed ID: 30849661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
    Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
    Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
    Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
    J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
    Minami Y; Minami H; Miyamoto T; Yoshimoto G; Kobayashi Y; Munakata W; Onishi Y; Kobayashi M; Ikuta M; Chan G; Woolfson A; Ono C; Shaik MN; Fujii Y; Zheng X; Naoe T
    Cancer Sci; 2017 Aug; 108(8):1628-1633. PubMed ID: 28556364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
    Savona MR; Pollyea DA; Stock W; Oehler VG; Schroeder MA; Lancet J; McCloskey J; Kantarjian HM; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Cortes JE
    Clin Cancer Res; 2018 May; 24(10):2294-2303. PubMed ID: 29463550
    [No Abstract]   [Full Text] [Related]  

  • 9. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
    Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
    Shimoda K; Komatsu N; Matsumura I; Ikeda K; Hino M; Hidaka M; Maeda Y; Kondo T; Fujisaki T; Shoshi K; Azuma K; Fukushima R; Kawashima J; Kosugi H
    Int J Hematol; 2024 Sep; 120(3):314-324. PubMed ID: 39110143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
    Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
    Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
    Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
    Oritani K; Ohishi K; Okamoto S; Kirito K; Komatsu N; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Okada H; Amagasaki T; Wakase S; Shimozuma K; Akashi K
    Curr Med Res Opin; 2018 Mar; 34(3):531-537. PubMed ID: 29224367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.